NCT00879814

Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults

A Phase 1 Randomized, Open-label, Parallel-group, Active- And Placebo-controlled Study To Assess Safety And Tolerability Of 60, 120, And 200 Mcg Meningococcal Group B Rlp2086 Vaccine In Healthy Adult Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 48 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years – 40 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and tolerability of an investigational meningococcal B rLP2086 vaccine in healthy adults.

Conditions

• Meningitis, Meningococcal

Interventions

Type	Name	Description
BIOLOGICAL	rLP2086 vaccine or control	intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
BIOLOGICAL	rLP2086 vaccine or control	intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
BIOLOGICAL	rLP2086 vaccine or control	intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
BIOLOGICAL	rLP2086 vaccine or control	intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months

Timeline

• Start date: 2009-04-01
• Primary completion: 2012-07-01
• Completion: 2012-07-01
• First posted: 2009-04-13
• Last updated: 2015-08-06
• Results posted: 2014-11-25

Locations

1 site across 1 country: United States